Galectin Therapeutics (GALT) Depreciation & Amortization (CF) (2010 - 2017)
Galectin Therapeutics' (GALT) quarterly Depreciation & Amortization (CF) came in at $1000.0 in Q1 2017, little changed year-on-year from $1000.0 in Q1 2016, and down 50.0% quarter-over-quarter from $2000.0 in Q4 2016.
Galectin Therapeutics (GALT) Depreciation & Amortization (CF) (2010 - 2017) Analysis & Trends
Galectin Therapeutics' Depreciation & Amortization (CF) history runs 8 years deep, the most recent figure standing at $1000.0 for Q1 2017.
- On a quarterly basis, Depreciation & Amortization (CF) changed 0.0% year-over-year to $1000.0 in Q1 2017; TTM through Dec 2017 was $1000.0, a 85.71% decrease from a year earlier, with the FY2017 full-year figure at $1000.0, down 85.71% from the prior year.
- Depreciation & Amortization (CF) fell to $1000.0 in Q1 2017 per GALT's latest filing, from $2000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $3000.0 in Q1 2013 and bottomed at $1000.0 in Q4 2015.
- The 5-year median for Depreciation & Amortization (CF) is $2000.0 (2014), against an average of $2176.5.
- Across the five-year window, Depreciation & Amortization (CF) jumped 200.0% in 2013 and sank 50.0% in 2015, its largest moves.
- Year by year, Depreciation & Amortization (CF) stood at $3000.0 in 2013, then tumbled by 33.33% to $2000.0 in 2014, then sank by 50.0% to $1000.0 in 2015, then soared by 100.0% to $2000.0 in 2016, then sank by 50.0% to $1000.0 in 2017.
- Per Business Quant, the three latest GALT Depreciation & Amortization (CF) figures stand at $1000.0 (Q1 2017), $2000.0 (Q4 2016), and $2000.0 (Q3 2016).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 41.14 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 91,781.47 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.20 Mn |
| 10 | Galectin Therapeutics | 227.21 Mn | 227.21 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2017 | 1,000.00 |
| Mar 31, 2017 | 1,000.00 |
| Dec 31, 2016 | 2,000.00 |
| Dec 31, 2016 | 2,000.00 |
| Sep 30, 2016 | 2,000.00 |
| Sep 30, 2016 | 2,000.00 |
| Jun 30, 2016 | 2,000.00 |
| Jun 30, 2016 | 2,000.00 |
| Mar 31, 2016 | 1,000.00 |
| Mar 31, 2016 | 1,000.00 |
| Dec 31, 2015 | 1,000.00 |
| Dec 31, 2015 | 1,000.00 |
| Sep 30, 2015 | 2,000.00 |
| Sep 30, 2015 | 2,000.00 |
| Jun 30, 2015 | 2,000.00 |
| Jun 30, 2015 | 2,000.00 |
| Mar 31, 2015 | 2,000.00 |
| Mar 31, 2015 | 2,000.00 |
| Dec 31, 2014 | 2,000.00 |
| Dec 31, 2014 | 2,000.00 |